Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LEGEND BIOTECH CORPORATION

(LEGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
54.11(c) 51.51(c) 49.84(c) 48.66(c) 44.39(c) Last
557 133 4 681 196 500 600 519 719 559 110 Volume
-0.06% -4.81% -3.24% -2.37% -8.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 66,6 M - -
Net income 2021 -402 M - -
Net cash position 2021 297 M - -
P/E ratio 2021 -30,8x
Yield 2021 -
Sales 2022 368 M - -
Net income 2022 -291 M - -
Net cash position 2022 335 M - -
P/E ratio 2022 -47,3x
Yield 2022 -
Capitalization 5 904 M 5 904 M -
EV / Sales 2021 84,2x
EV / Sales 2022 15,1x
Nbr of Employees 882
Free-Float 6,93%
More Financials
Company
Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Legend Biotech Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about LEGEND BIOTECH CORPORATION
11/16Legend Biotech's Loss Widens, Revenue Rises in Q3
MT
11/16LEGEND BIOTECH : Reports Third Quarter 2021 Financial Results and Recent Highlights - Form..
PU
11/16Earnings Flash (LEGN) LEGEND BIOTECH Posts Q3 Loss $-0.43
MT
11/16Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
BU
11/16Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04Genscript's Nasdaq-Listed Arm to Present 12 Sponsored Studies at American Society of He..
MT
11/04Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..
PU
11/04Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..
BU
11/04Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..
CI
11/01US FDA Extends Approval Target Date for Genscript Biotech's Myeloma Drug; Shares Fall 8..
MT
11/01Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel - Form 6-K
PU
11/01Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
BU
11/01Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
CI
10/28Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
AQ
10/18GENSCRIPT BIOTECH : Nasdaq-listed Arm to Present Preclinical, Clinical Trial Data of Cance..
MT
More news
News in other languages on LEGEND BIOTECH CORPORATION
11/16La perte de Legend Biotech se creuse, mais les recettes augmentent au troisième trimest..
11/04La branche de Genscript cotée au Nasdaq présentera 12 études parrainées lors du congrès..
11/01La FDA américaine repousse la date cible d'approbation du médicament contre le myélome ..
10/18La branche de Genscript Biotech cotée au Nasdaq présentera des données d'essais préclin..
09/23L'unité de Genscript Bio cotée au Nasdaq organise la première journée de la recherche e..
More news
Analyst Recommendations on LEGEND BIOTECH CORPORATION
More recommendations
Chart LEGEND BIOTECH CORPORATION
Duration : Period :
Legend Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEGEND BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 44,39 $
Average target price 63,60 $
Spread / Average Target 43,3%
EPS Revisions
Managers and Directors
Ying Huang Chief Executive & Financial Officer
Ye Wang Chairman
Frank Fan Chief Scientific Officer
Corsee Dating Sanders Independent Director
Darren Ji Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LEGEND BIOTECH CORPORATION76.99%5 904
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819